DNER and acute myeloid leukemia: We have previously shown in a murine AML model that acquired therapeutic resistance to BET inhibitors, an epigenetic therapy capable of inducing complete remissions in AML patients12,13, emerges in the absence of new genetic mutations from leukaemia stem cells (LSC)6.